High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Intensive Care Med. 2020 Jun;46(6):1089-1098. doi: 10.1007/s00134-020-06062-x. Epub 2020 May 4.

Abstract

Purpose: Little evidence of increased thrombotic risk is available in COVID-19 patients. Our purpose was to assess thrombotic risk in severe forms of SARS-CoV-2 infection.

Methods: All patients referred to 4 intensive care units (ICUs) from two centers of a French tertiary hospital for acute respiratory distress syndrome (ARDS) due to COVID-19 between March 3rd and 31st 2020 were included. Medical history, symptoms, biological data and imaging were prospectively collected. Propensity score matching was performed to analyze the occurrence of thromboembolic events between non-COVID-19 ARDS and COVID-19 ARDS patients.

Results: 150 COVID-19 patients were included (122 men, median age 63 [53; 71] years, SAPSII 49 [37; 64] points). Sixty-four clinically relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms (16.7%). 28/29 patients (96.6%) receiving continuous renal replacement therapy experienced circuit clotting. Three thrombotic occlusions (in 2 patients) of centrifugal pump occurred in 12 patients (8%) supported by ECMO. Most patients (> 95%) had elevated D-dimer and fibrinogen. No patient developed disseminated intravascular coagulation. Von Willebrand (vWF) activity, vWF antigen and FVIII were considerably increased, and 50/57 tested patients (87.7%) had positive lupus anticoagulant. Comparison with non-COVID-19 ARDS patients (n = 145) confirmed that COVID-19 ARDS patients (n = 77) developed significantly more thrombotic complications, mainly pulmonary embolisms (11.7 vs. 2.1%, p < 0.008). Coagulation parameters significantly differed between the two groups.

Conclusion: Despite anticoagulation, a high number of patients with ARDS secondary to COVID-19 developed life-threatening thrombotic complications. Higher anticoagulation targets than in usual critically ill patients should therefore probably be suggested.

Keywords: ARDS; COVID-19; Coagulopathy; Lupus anticoagulant; Thrombosis.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Anticoagulants / therapeutic use*
  • Betacoronavirus / pathogenicity*
  • Coronavirus Infections / mortality
  • Coronavirus Infections / physiopathology*
  • Coronavirus Infections / therapy
  • Critical Illness
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis
  • Fibrin Fibrinogen Degradation Products / metabolism*
  • France / epidemiology
  • Humans
  • Intensive Care Units
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / mortality
  • Pneumonia, Viral / physiopathology*
  • Pneumonia, Viral / therapy
  • Propensity Score
  • Prospective Studies
  • Pulmonary Embolism / complications
  • Pulmonary Embolism / mortality
  • Pulmonary Embolism / physiopathology*
  • Pulmonary Embolism / virology
  • Severe Acute Respiratory Syndrome / complications
  • Severe Acute Respiratory Syndrome / mortality
  • Severe Acute Respiratory Syndrome / physiopathology*
  • Severe Acute Respiratory Syndrome / virology
  • Thrombosis / etiology
  • Thrombosis / mortality
  • Thrombosis / physiopathology*
  • Thrombosis / virology

Substances

  • Anticoagulants
  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D

Supplementary concepts

  • COVID-19
  • severe acute respiratory syndrome coronavirus 2